首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Variant-type PML-RARα fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RARα gene and identification of a new clinical subtype resistant to retinoic acid therapy
【24h】

Variant-type PML-RARα fusion transcript in acute promyelocytic leukemia: Use of a cryptic coding sequence from intron 2 of the RARα gene and identification of a new clinical subtype resistant to retinoic acid therapy

机译:急性早幼粒细胞白血病中的变异型PML-RARα融合转录本:RARα基因内含子2的密码子编码序列的使用和鉴定对视黄酸有抗药性的新临床亚型

获取原文
获取原文并翻译 | 示例
           

摘要

The physiologic actions of retinoic acids (RAs) are mediated through RA receptors (RARs) and retinoid X receptors (RXRs). The RARα gene has drawn particular attention because it is the common target in all chromosomal translocations in acute promyelocytic leukemia (APL), a unique model in cancer research that responds to the effect of RA. In the great majority of patients with APL, RARα is fused to the PML gene as a result of the t(15;17) translocation. Three distinct types of PML-RARα transcripts, long (L), short (S), and variant (V), were identified.
机译:视黄酸(RA)的生理作用是通过RA受体(RAR)和类维生素X受体(RXR)介导的。 RARα基因引起了人们的特别关注,因为它是急性早幼粒细胞白血病(APL)中所有染色体易位的共同靶标,而APL是癌症研究中对RA产生反应的独特模型。在大多数APL患者中,由于t(15; 17)易位,RARα与PML基因融合。确定了三种不同类型的PML-RARα转录本,长(L),短(S)和变异(V)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号